UPDATE 1-Gilead to acquire Arcellx for $7.8 billion

Arcellx, Inc. +0.09%
Gilead Sciences, Inc. -0.87%

Arcellx, Inc.

ACLX

115.10

+0.09%

Gilead Sciences, Inc.

GILD

138.55

-0.87%

Adds shares in first paragraph, deal details in paragraph 3

Feb 23 (Reuters) - Gilead Sciences GILD.O said on Monday it will buy cancer therapy developer Arcellx ACLX.O for an implied equity value of $7.8 billion, sending shares of Arcellx climbing 77.8% to $113.99 in premarket trading.

Gilead will pay $115 per share in cash at the deal's closing and one contingent value right of $5 per share, which is a premium of 87% to the stock's last close.


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.